| Literature DB >> 26315122 |
Branca M A Silva1, Ana Filipa Borges2, Cláudia Silva3, Jorge F J Coelho4, Sérgio Simões2.
Abstract
Oral drug delivery is the most common route of drug administration. Nevertheless, there are some important limitations that reinforce the need for developing new drug delivery systems. Mucoadhesive oral films (MOF) are promising dosage forms that adhere to the oral mucosa and deliver the drug through it, which present several advantages. These include: bypassing the hepatic first pass effect, fast onset of action, ease of transportation and handling. The use of such dosage form is beneficial for drugs that have poor oral bioavailability and also for drugs that need to be rapidly absorbed. In spite of the known benefits, the number of marketed MOF is still quite small. This review explores the products under development and corresponding clinical trials in respect to their status, therapeutic indication, companies involved and technologies. In this way, it was possible to identify the preferred therapeutic indications, new research and market trends as well as future prospects of MOF. Moreover, it is reasonable to expect an increase in the number of products on the market due to their great potential to satisfy unmet medical needs.Entities:
Keywords: Buccal films; Migraines; Mucoadhesive films; Opioid dependence; Pain; Sublingual films
Mesh:
Substances:
Year: 2015 PMID: 26315122 DOI: 10.1016/j.ijpharm.2015.08.038
Source DB: PubMed Journal: Int J Pharm ISSN: 0378-5173 Impact factor: 5.875